HealthEli Lilly CEO: One-Third of New GLP-1 Patients Use Foundayo Pill
Eli Lilly CEO David Ricks revealed that about one-third of new patients prescribed the GLP-1 receptor agonist tirzepatide are choosing the oral pill form called Foundayo. In response to this growing demand, Eli Lilly is significantly ramping up production of the drug. This highlights increased patient preference and accessibility for the oral GLP-1 therapy.
Indiavision India News & Information··Indianapolis


